# CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia

> **NCT04004637** · PHASE1 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- T-lymphoblastic Lymphoma
- NK/T Cell Lymphoma
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** CD7 CAR-T cells infusion

## Key facts

- **NCT ID:** NCT04004637
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-25
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004637, "CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04004637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*